What BioAdvance does

BioAdvance is a Pennsylvania-based evergreen venture capital fund that provides seed and Series A funding to early-stage life science companies headquartered in the Mid-Atlantic U.S. I-95 corridor (Pennsylvania, New Jersey, Delaware, Maryland, Washington DC, and parts of New York and Virginia). Founded in 2002, the fund has invested in 120+ companies across five sector tracks: Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. Initial investment sizes typically range from $500,000 to $1,500,000, with the ability to commit up to $5,000,000 over a portfolio company's lifecycle. The fund reports 28 exits, 12 FDA-approved products, and over $4.4 billion in follow-on capital attracted by portfolio companies from third-party investors.

BioAdvance's investment model is differentiated by its evergreen fund structure (perpetual life, no fixed fund-end), which allows it to hold positions for the full 10-15+ year arc of life science development without forced exits. The fund's competitive position rests on its regional mandate and dominance in the Mid-Atlantic corridor, where locally headquartered life science VCs are scarce relative to Boston and San Francisco. The team of approximately 12 (7 staff plus 5 advisors/EIRs) combines operating leadership from major pharma/medtech (Kodak, Siemens, J&J, Amgen, Merck, GSK, Pfizer) with academic and policy ties (University of Pennsylvania, Princeton, PA Department of Community & Economic Development), enabling both sector diligence and syndication across 8VC, DCVC Bio, Modi Ventures, and others.

The fund's economic model relies on capital appreciation from portfolio exits (28 realized to date), supported by capital-efficient investment philosophy and strong co-investor syndication. BioAdvance does not develop proprietary technology; its "product" is capital deployment plus operational support, board participation, and follow-on investor introductions. Notable active portfolio companies include Latus Bio (AAV gene therapy), ImmunoGenesis (immuno-oncology), Wellsheet (clinical workflow, acquired by Elsevier in 2026), Strados Labs (respiratory monitoring), and KaloCyte (synthetic blood substitute).

Name

BioAdvance

Legal name

BioAdvance

Website

https://bioadvance.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

BioAdvance is a Pennsylvania-based evergreen venture capital fund providing $500K-$1.5M seed and Series A investments to early-stage life science companies in the Mid-Atlantic U.S. I-95 corridor, with 120+ portfolio companies across therapeutics, devices, digital health, diagnostics, and research tools.

Ownership category

akta.pro rank

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Investment returns from portfolio exits (evergreen fund model):

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

BioAdvance is a privately held, evergreen venture capital fund that invests $500,000–$1,500,000 in seed and Series A rounds (with reserves up to $5,000,000 per company over its lifecycle) in early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor from NYC to DC). The fund deploys capital across five sector tracks — Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools — and provides operational support, board participation, and introductions to follow-on investors alongside its core equity investment.

Product overview

BioAdvance Capital is a single, unified evergreen venture capital fund (not a multi-product SaaS platform) that provides seed and Series A funding to early-stage life science companies. The fund is structured around a single core investment service (the seed/Series A investment program) that is deployed across five distinct sector tracks: Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. BioAdvance does not sell these as separate products; rather, they represent the five sector verticals in which the fund actively invests. Across these verticals, the firm has backed 120+ portfolio companies that together have attracted over $4.4 billion in follow-on external capital, and the fund itself has committed over $50 million to almost 100 seed-stage companies during Barbara Schilberg's tenure as CEO (2002-2021). Notable active portfolio companies include Latus Bio (AAV gene therapy), Ladder Bio (Spiroligomer platform), ImmunoGenesis (immunotherapy), Wellsheet (AI clinical workflows), and KaloCyte (synthetic blood substitute).

Differentiator

Problem solved

Functional benefit

Products and services

• Seed-Stage Life Sciences Investment Program Core equity investment program providing seed and Series A funding (initial checks of $500,000–$1,500,000, up to $5,000,000 over a company's lifecycle) to early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor between NYC and Washington, D.C.). Designed to help companies reach critical de-risking or value-inflection milestones.
• Therapeutics Investment Track Sector-specific investment track for therapeutic innovations including novel small molecules, gene therapies (e.g., AAV-based platforms), antibodies, and cell therapies addressing significant unmet needs in human health.
• Medical Devices Investment Track Sector-specific investment track for medical device companies developing novel hardware, diagnostics devices, and procedural technologies for the healthcare market.
• Digital Health Investment Track Sector-specific investment track for digital health companies with proven product-market-fit and established market traction as demonstrated by a growing revenue stream. Includes AI clinical workflow, SaaS, and clinician retention intelligence platforms.
• Diagnostics Investment Track Sector-specific investment track for diagnostics companies developing novel testing platforms, rapid assay-based (RQA) products, point-of-care diagnostics, and imaging agents.
• Research Tools Investment Track Sector-specific investment track for research tools companies that provide enabling technologies, platforms, and consumables for academic and pharmaceutical research and drug discovery.

Quantifiable outcome

• 120+ companies invested in since inception
• +5 more outcomes

Named customers13 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered strategic ecosystem partner and ecosystem partner.

• University of Pennsylvania (Penn Medicine)strategic ecosystem partnerStrategic or Co-development PartnerThe Dean of the University of Pennsylvania School of Medicine and EVP of the Health System (Jonathan Epstein, M.D.) serves on the BioAdvance Board of Directors, reflecting a strategic relationship with Penn Medicine — a key source of translational research and spinout deal flow for BioAdvance in the Philadelphia region.
• Pennsylvania Department of Community & Economic Development (DCED), Office of Technology & Entrepreneurshipstrategic ecosystem partnerOthersThe Deputy Secretary of the PA DCED Office of Technology & Entrepreneurship (Jen Gilburg) serves on the BioAdvance Board of Directors, evidencing a close relationship with the Commonwealth of Pennsylvania's technology and life science economic-development apparatus. The Commonwealth has historically supported BioAdvance's evergreen fund structure through state allocations.
• Princeton Universityecosystem partnerStrategic or Co-development PartnerBioAdvance CEO Shahram Hejazi is a lecturer at Princeton University's School of Engineering, providing BioAdvance with a direct line into Princeton's translational research and student/faculty entrepreneurship pipeline in the Mid-Atlantic.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ben Franklin Technology Partners: Pennsylvania-based, state-affiliated seed and early-stage investor focused on technology and life sciences. Closest analog to BioAdvance in mission, regional mandate, evergreen orientation, and stage focus; co-invests with BioAdvance in multiple portfolio companies (e.g., Latus Bio).
• Broadview Ventures: Boston-based early-stage life sciences venture fund focused on cardiovascular and CNS therapeutics. Directly comparable in stage (seed/Series A), sector focus, and evergreen/patient-capital orientation; Rick Jones of BioAdvance's team previously served as a Director there.

Regional players

• BioEnterprise: Midwest (Cleveland) regional life science commercialization organization and investor in therapeutics, medical devices, and diagnostics. Comparable as a regional life science investor focused on company formation and seed-stage capital, though operating in a different geography.
• Life Sciences Greenhouse of Central PA: Pennsylvania-focused life science seed fund with a similar mission of supporting early-stage companies within the state. Comparable regional mandate and stage focus, though narrower geographic scope within PA.
• Robin Hood Ventures: Philadelphia-area angel investing group that focuses on early-stage companies in the Mid-Atlantic. Gregory Harriman of BioAdvance is a member; comparable in regional focus and stage, though broader sector mandate.

Broad incumbents

• Mass General Brigham Ventures: Hospital-system-affiliated venture arm investing in therapeutics, medtech, and digital health. Comparable in sector focus and mission-driven orientation, though anchored to a single health system and broader portfolio scope than BioAdvance.
• ARCH Venture Partners: Large, established life science venture firm investing across stages from formation to public company. Operates broadly in BioAdvance's core therapeutic verticals but at much larger check sizes and without a regional mandate.
• Atlas Venture: Boston-based early-stage life sciences venture firm with a similar focus on building biotechs from inception. Comparable in stage and therapeutic orientation, but operates nationally and globally with substantially more capital.
• New Enterprise Associates (NEA): One of the largest U.S. venture firms with a dedicated healthcare practice investing across therapeutics, medical devices, and digital health at all stages. Operates broadly in BioAdvance's core verticals and increasingly at seed/Series A where BioAdvance competes.

Emerging players

• Cedars-Sinai Accelerator: Hospital-affiliated accelerator investing in early-stage health technology and digital health companies. Comparable in seed-stage health-tech orientation and ecosystem-driven model, though focused on a single health system in Los Angeles.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioadvance

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments190 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAdvance